Journal
JOURNAL OF CLINICAL MEDICINE
Volume 11, Issue 15, Pages -Publisher
MDPI
DOI: 10.3390/jcm11154475
Keywords
hepatocellular carcinoma; COVID-19; SARS-CoV-2; liver cancer
Categories
Ask authors/readers for more resources
The COVID-19 outbreak has significantly impacted healthcare systems worldwide, particularly for patients with hepatocellular carcinoma (HCC). Reshaping clinical practice is necessary to ensure patient care and safety. Due to the pandemic measures, HCC surveillance has decreased and care for HCC patients has been rearranged.
Worldwide, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) significantly increases mortality and morbidity. The Coronavirus Disease 2019 (COVID-19) outbreak has had a considerable impact on healthcare systems all around the world, having a significant effect on planned patient activity and established care pathways, in order to meet the difficult task of the global pandemic. Patients with hepatocellular carcinoma (HCC) are considered a particularly susceptible population and conceivably at increased risk for severe COVID-19 because of two combined risk factors: chronic advanced liver disease and HCC itself. In these challenging times, it is mandatory to reshape clinical practice in a prompt way to preserve the highest standards of patient care and safety. However, due to the stay-at-home measures instituted to stop the spread of COVID-19, HCC surveillance has incurred a dramatic drop, and care for HCC patients has been rearranged by refining the algorithm for HCC treatment to the COVID-19 pandemic, permitting these patients to be safely managed by identifying those most at risk of neoplastic disease progression.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available